Dr. Stephen Cederbaum Recognized with 2025 David L. Rimoin Award
In a prestigious announcement, renowned clinical geneticist Dr. Stephen Cederbaum has been selected as the recipient of the 2025 David L. Rimoin Lifetime Achievement Award from the ACMG Foundation for Genetic and Genomic Medicine. This award is a testament to his remarkable career and contributions to the field of medical genetics, particularly in understanding and treating inborn errors of metabolism.
Dr. Cederbaum, who holds advanced degrees including an MD and PhD, has made a significant impact throughout his career, spanning over fifty years. He is a distinguished professor emeritus at UCLA, where he has profoundly influenced the study of genetic disorders. His most notable work has been in urea cycle disorders, specifically arginase deficiency, a rare condition caused by the body’s inability to process ammonia, which can lead to severe health issues if untreated.
His journey in this specialized field began in 1972, and over the decades, he has dedicated his efforts to outlining both the biochemistry and pathology of arginase deficiency. His commitment to this disorder led him to develop clinical programs at UCLA and engage in extensive research that included creating animal models to explore gene replacement therapies, significantly advancing the understanding and treatment options available for patients.
Brendan Lee, MD, PhD, highlighted Dr. Cederbaum’s unparalleled ability to bridge the gaps between clinical care, biochemistry, and genetics, stating, "His scientific insights have been invaluable, and his humble approach to leadership has set an example for many in the field."
Beyond his research endeavors, Dr. Cederbaum’s advocacy for public health is notable. His efforts were crucial in expanding newborn screening programs to include advanced technologies like mass spectrometry, which significantly improves the early detection of metabolic disorders in infants. He also led initiatives to ensure that adults suffering from inborn metabolic errors received adequate support and care, rallying for policy changes that would improve access to healthcare resources.
In addition to his scientific and clinical accomplishments, Dr. Cederbaum has been a dedicated mentor and educator. He founded the ARD1-D Foundation, a support group geared towards families affected by arginase deficiency, emphasizing his commitment to community and patient support. Marshall Summar, MD, recognized his unwavering dedication, stating that Dr. Cederbaum's humility and recognition of his team's efforts is exemplary.
Dr. Cederbaum's scholarly contributions include over 180 peer-reviewed articles and numerous book chapters, making him a leading voice in medical genetics. His pioneering research has not only clarified the treatment pathways for arginase deficiency but also opened up new investigations into related conditions such as pyruvate dehydrogenase deficiency.
Graduating from Amherst College with a degree in chemistry and later receiving his medical degree from New York University, Dr. Cederbaum’s academic journey reflects a deep-rooted passion for science and patient care. He continued his education with specialized training in medical genetics, setting the stage for a career that would break new ground in understanding genetic conditions.
The honor from the ACMG Foundation recognizes Dr. Cederbaum’s lifelong contributions to genetic medicine, as well as his role as a leader and innovator in the field. His dedication encapsulates the core values of the award, celebrating a career filled with teaching, mentorship, and an unwavering commitment to advancing healthcare for individuals with genetic disorders.
Even after decades in the field, Dr. Cederbaum’s enthusiasm remains undiminished. He emphasizes the profound significance of the human connection in medical practice, indicating that his interactions with patients have always been a primary motivator in his career. As he continues to influence and inspire the next generation of medical professionals, his legacy is set to endure long into the future.
The David L. Rimoin Lifetime Achievement Award is the highest recognition awarded by the ACMG Foundation, symbolizing the highest standards of excellence in genetic and genomic medicine. The honor is reserved for those who have made significant, lasting contributions that advance the field and improve patient care.
In summary, Dr. Stephen Cederbaum’s career stands as a monumental example of dedication, innovation, and compassion in the realm of medical genetics. His receipt of the 2025 David L. Rimoin Lifetime Achievement Award not only acknowledges his past accomplishments but also sets the standard for future generations of geneticists and healthcare advocates.
Dr. Cederbaum, who holds advanced degrees including an MD and PhD, has made a significant impact throughout his career, spanning over fifty years. He is a distinguished professor emeritus at UCLA, where he has profoundly influenced the study of genetic disorders. His most notable work has been in urea cycle disorders, specifically arginase deficiency, a rare condition caused by the body’s inability to process ammonia, which can lead to severe health issues if untreated.
His journey in this specialized field began in 1972, and over the decades, he has dedicated his efforts to outlining both the biochemistry and pathology of arginase deficiency. His commitment to this disorder led him to develop clinical programs at UCLA and engage in extensive research that included creating animal models to explore gene replacement therapies, significantly advancing the understanding and treatment options available for patients.
Brendan Lee, MD, PhD, highlighted Dr. Cederbaum’s unparalleled ability to bridge the gaps between clinical care, biochemistry, and genetics, stating, "His scientific insights have been invaluable, and his humble approach to leadership has set an example for many in the field."
Beyond his research endeavors, Dr. Cederbaum’s advocacy for public health is notable. His efforts were crucial in expanding newborn screening programs to include advanced technologies like mass spectrometry, which significantly improves the early detection of metabolic disorders in infants. He also led initiatives to ensure that adults suffering from inborn metabolic errors received adequate support and care, rallying for policy changes that would improve access to healthcare resources.
In addition to his scientific and clinical accomplishments, Dr. Cederbaum has been a dedicated mentor and educator. He founded the ARD1-D Foundation, a support group geared towards families affected by arginase deficiency, emphasizing his commitment to community and patient support. Marshall Summar, MD, recognized his unwavering dedication, stating that Dr. Cederbaum's humility and recognition of his team's efforts is exemplary.
Dr. Cederbaum's scholarly contributions include over 180 peer-reviewed articles and numerous book chapters, making him a leading voice in medical genetics. His pioneering research has not only clarified the treatment pathways for arginase deficiency but also opened up new investigations into related conditions such as pyruvate dehydrogenase deficiency.
Graduating from Amherst College with a degree in chemistry and later receiving his medical degree from New York University, Dr. Cederbaum’s academic journey reflects a deep-rooted passion for science and patient care. He continued his education with specialized training in medical genetics, setting the stage for a career that would break new ground in understanding genetic conditions.
The honor from the ACMG Foundation recognizes Dr. Cederbaum’s lifelong contributions to genetic medicine, as well as his role as a leader and innovator in the field. His dedication encapsulates the core values of the award, celebrating a career filled with teaching, mentorship, and an unwavering commitment to advancing healthcare for individuals with genetic disorders.
Even after decades in the field, Dr. Cederbaum’s enthusiasm remains undiminished. He emphasizes the profound significance of the human connection in medical practice, indicating that his interactions with patients have always been a primary motivator in his career. As he continues to influence and inspire the next generation of medical professionals, his legacy is set to endure long into the future.
The David L. Rimoin Lifetime Achievement Award is the highest recognition awarded by the ACMG Foundation, symbolizing the highest standards of excellence in genetic and genomic medicine. The honor is reserved for those who have made significant, lasting contributions that advance the field and improve patient care.
In summary, Dr. Stephen Cederbaum’s career stands as a monumental example of dedication, innovation, and compassion in the realm of medical genetics. His receipt of the 2025 David L. Rimoin Lifetime Achievement Award not only acknowledges his past accomplishments but also sets the standard for future generations of geneticists and healthcare advocates.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.